Absci is trading 6.54% down at $9.00 after no confirmed company-specific announcement was identified for August 26, 2026.
- The latest major company update was August 11, when Absci reported positive interim ABS-201 Phase 1 data and a $100 million offering that included a $40 million Eli Lilly investment.
- Biotech-sector strength does not explain the decline: XBI is rising while Absci falls.
- Broader indexes are nearly flat, leaving the specific catalyst unclear.